Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes

1064PA PHASE 1 STUDY OF ENADENOTUCIREV, AN ONCOLYTIC AD11/AD3 CHIMERIC GROUP B ADENOVIRUS, ADMINISTERED INTRAVENOUSLY - ANALYSIS OF DOSE EXPANSION AND REPEAT CYCLE COHORTS IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC)

(2017) E. Calvo et al.   ANNALS OF ONCOLOGY

Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges

(2016) Francesca Tartari et al.   CANCER TREATMENT REVIEWS

Immune-Related Adverse Events From Immune Checkpoint Inhibitors

(2016) KA Marrone et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

(2016) J.M. Michot et al.   EUROPEAN JOURNAL OF CANCER

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

Immune-checkpoint blockade — durable cancer control

(2016) Elizabeth I. Buchbinder et al.   Nature Reviews Clinical Oncology

Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations

(2016) Axel Hoos   NATURE REVIEWS DRUG DISCOVERY

Pembrolizumab for the treatment of advanced melanoma

(2016) Michael C. Burns et al.   Expert Opinion on Orphan Drugs

Talimogene Laherparepvec: First Global Approval

(2015) Sarah L. Greig   DRUGS

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor

(2015) S. Tahtinen et al.   Cancer Immunology Research

Trial Watch—Oncolytic viruses and cancer therapy

(2015) Jonathan Pol et al.   OncoImmunology

Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood

(2014) Y Di et al.   GENE THERAPY

Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy

(2014) D. Zamarin et al.   Science Translational Medicine

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Immunogenic HSV-mediated Oncolysis Shapes the Antitumor Immune Response and Contributes to Therapeutic Efficacy

(2013) Samuel T Workenhe et al.   MOLECULAR THERAPY

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

(2013) Jeong Heo et al.   NATURE MEDICINE

Recombinant viral vaccines for cancer

(2012) Ryan Cawood et al.   TRENDS IN MOLECULAR MEDICINE

Real-time PCR-based assay to quantify the relative amount of human and mouse tissue present in tumor xenografts

(2011) Sergio Y Alcoser et al.   BMC BIOTECHNOLOGY

Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma

(2009) Howard L. Kaufman et al.   ANNALS OF SURGICAL ONCOLOGY

Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1

(2009) R. C. Carlisle et al.   BLOOD

Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer

(2008) Irene Kuhn et al.   PLoS One